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Objectives
To evaluate the occurrence of severe urinary complications
within 2 years of surgery in men undergoing either robot-
assisted radical prostatectomy (RARP), laparoscopic radical
prostatectomy (LRP) or retropubic open radical
prostatectomy (ORP).
Patients and Methods
We conducted a population-based cohort study in men who
underwent RARP (n = 4 947), LRP (n = 5 479) or ORP (n =
6 873) between 2008 and 2012 in the English National Health
Service (NHS) using national cancer registry records linked to
Hospital Episodes Statistics, an administrative database of
admissions to NHS hospitals. We identiﬁed the occurrence of
any severe urinary or severe stricture-related complication
within 2 years of surgery using a validated tool. Multi-level
regression modelling was used to determine the association
between the type of surgery and occurrence of complications,
with adjustment for patient and surgical factors.
Results
Men undergoing RARP were least likely to experience any
urinary complication (10.5%) or a stricture-related
complication (3.3%) compared with those who had LRP
(15.8% any or 5.7% stricture-related) or ORP (19.1% any
or 6.9% stricture-related). The impact of the type of
surgery on the occurrence of any urinary or
stricture-related complications remained statistically
signiﬁcant after adjustment for patient and surgical factors
(P < 0.01).
Conclusion
Men who underwent RARP had the lowest risk of
developing severe urinary complications within 2 years of
surgery.
Keywords
prostate cancer, radical prostatectomy, stricture, urinary
complications
Introduction
Robot-assisted radical prostatectomy (RARP) has been widely
adopted despite a paucity of evidence for its effectiveness
compared with retropubic open radical prostatectomy (ORP)
or laparoscopic radical prostatectomy (LRP) in terms of both
cancer and functional outcomes.
A number of studies have compared the occurrence of
urinary complications according to type of prostatectomy
[1–3]; however, many of these studies included patients from
a single surgeon or single institution, or recruited from a
tertiary centre. Population-based studies have also been
performed but these mainly used US Surveillance
Epidemiology and End Results (SEER)-Medicare cohorts
which have exclusions based on age and insurance status, and
the outcome measures used are not explicitly validated [4–6].
A recent randomized controlled trial comparing ORP and
RARP showed similar patient-reported urinary function in
the 3 months immediately after surgery in both groups [7];
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however, there is a gap in knowledge about the occurrence of
urinary complications in the medium and longer term
according to type of radical prostatectomy (RP).
In the present study, we used a validated outcome measure
[8] and ‘real-world’ data to compare severe medium-term
urinary complications after RARP, LRP and ORP in a
national cohort of all men with prostate cancer who
underwent RP in the English NHS system between 2008 and
2012.
Materials and Methods
Population
Using the International Classiﬁcation of Diseases, 10th
revision (ICD-10) codes [9], we identiﬁed men diagnosed
with prostate cancer (code C61) between 1 January 2008 and
31 December 2012 within the English national cancer registry
[10]. Linked records from the Hospital Episodes Statistics
(HES) database were used to identify men who underwent RP
using the UK Ofﬁce of Population Census and Surveys
classiﬁcation, 4th revision (OPCS-4; code M61) [11], as well
as their future hospital readmissions. HES is an
administrative database of all admissions to NHS hospitals in
England, and patient records contain a unique patient
identiﬁer that allows longitudinal follow-up [12].
Study Cohort and Main Exposure
The linked HES cancer registry records of 18 739 men
who underwent RP between 1 January 2008 and 31
December 2012 were studied. Men were excluded if they
could not be linked to an NHS provider (n = 345) or if
their socio-economic background according to the Index
of Multiple Deprivation [13] could not be determined (n
= 41; Fig. 1). Men with an associated diagnosis of
bladder cancer (n = 229, ICD-10 C61) were excluded
because their surveillance often requires interval
cystoscopies which could be incorrectly captured as a
treatment of a urinary complication. Men who received
adjuvant or salvage radiotherapy (n = 825) within 2 years
were excluded because it is not possible to distinguish
between complications that occurred as a consequence of
RP or the subsequent radiotherapy (OPCS-4 codes
deﬁned in Table S1). As a result, we included 17 299
men for whom we had complete data and at least 2 years
of follow-up.
Patients who had a code for a robot-assisted procedure
(OPCS-4 Y753 or Y765) in their HES records were classiﬁed
as having undergone RARP and those with a code for
laparoscopic procedure (OPCS-4 Y752, Y768, Y751 or Y508)
were classiﬁed as having undergone LRP. All other men who
underwent RP were classiﬁed as having undergone ORP.
Covariates
We examined relevant patient and surgical characteristics.
Data items in HES records were used to determine age, Royal
College of Surgeons Charlson comorbidity score [14], socio-
economic deprivation level [13], and whether a pelvic lymph
node dissection was performed at time of RP (Table S1
includes a detailed description of the coding framework). We
also determined the total number of RPs performed by each
surgical centre (n = 65) during the 5-year study period.
Hospitals were stratiﬁed into low- (<50 RPs/year), medium-
(50–100 RPs/year) and high-volume centres (>100 RPs/year)
based on volume thresholds used in the existing literature
and national UK policy guidelines [15,16].
Study Outcome
We used a previously developed and validated tool to capture
the occurrence of any urinary or stricture-related
complications severe enough to require an intervention [8].
In brief, we determined a list of interventions based on
OPCS-4 procedure codes used to treat urinary complications
that can occur after RP (Table S2). The occurrence of an
intervention acted as a marker of a severe urinary
complication and included procedures to treat postoperative
haematuria, strictures and urinary incontinence. We further
reﬁned the list of interventions so that we could identify men
who required speciﬁc surgical procedures used to treat a
urethral stricture. This approach conﬁned our analyses to
what were likely to be severe complications comparable with
grade 3 toxicity according to the National Cancer Institute
Common Toxicity Criteria for Adverse Events scoring system
(i.e. requiring hospital admission or procedural intervention)
[17]. All HES records of readmissions 2 years after RP were
examined to identify the proportion of men experiencing any
severe urinary complication and stricture-related
complications. Patients were considered not to have
experienced a complication if there were no hospital
readmissions in the ﬁrst 2 years after RP or if there were no
relevant procedure codes in the procedural ﬁelds of a
readmission. Our methodology met seven of the 10 Martin
criteria for reporting complications after urological surgery
according to the European Association of Urology guidelines
[18].
Statistical Analyses
Kaplan–Meier methods were used to describe the time to the
ﬁrst occurrence of a severe urinary complication according to
type of prostatectomy. This was also performed separately for
stricture-related complications.
Multi-level regression modelling was used to assess the
impact of type of prostatectomy on the occurrence of urinary
complications with adjustment for patient-level factors (age,
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comorbidity and socio-economic deprivation) and surgical
factors (use of pelvic lymph node dissection), and to assess
the effect of RP volume as a hospital-level factor. Results are
reported as odds ratios (ORs) and a P value < 0.05 was taken
to indicate statistical signiﬁcance. P values were based on the
Wald test or the likelihood ratio test, as appropriate.
Results
Trends over Study Period
Of the 17 299 men included in the study, 6 873 (39.7%)
underwent ORP, 5 479 (31.7%) underwent LRP and the
remaining 4 947 (28.6%) underwent RARP (Table 1). Over
the 5-year study period, the proportion of men undergoing
ORP fell from 61.3% to 28.4%, while the proportion of men
undergoing RARP and LRP increased from 14.0% to 40.1%
and from 24.8% to 31.4%, respectively (Table 1).
Overall, patients undergoing both RARP and LRP tended to
be younger and to come from more afﬂuent backgrounds
than men undergoing ORP (Table 1). Furthermore, men
undergoing RARP tended to have fewer comorbidities than
men undergoing LRP or ORP. Patients undergoing ORP were
more likely to have a pelvic lymph node dissection than those
undergoing LRP or RARP. RARP was also more likely to be
performed in a high-volume centre than both LRP and ORP.
Impact of Type of Radical Prostatectomy on Urinary
Complications
A total of 10.5% of men who received RARP experienced a
urinary complication severe enough to require an intervention
within 2 years of RP compared with 15.8% of men
undergoing LRP and 19.1% of men undergoing ORP (Table 2
and Fig. 2). After adjustment, multi-level analysis showed that
men who underwent RARP were less likely to experience a
urinary complication than men who underwent ORP
(adjusted OR 0.67; 95% CI 0.58–0.78) and the rate was also
Missing Data Exclusions (n=386):
345 men excluded not matched to RP provider 
41 men excluded with missing deprivation status
information
Final Cohort
17 299
Clinical Exclusions (n=1054)
229 men excluded with additional diagnosis of 
Bladder Cancer
825 men excluded who received adjuvant/salvage 
radiotherapy
Men receiving radical prostatectomy from 2008–2012
(HES/National Cancer Registry)
18 739
Fig. 1 Flow chart of men included in study. HES, Hospital Episode Statistics; RP, radical prostatectomy.
Table 1 Patient and surgical characteristics of 17 299 men undergoing
prostatectomy.
Type of RP ORP, n (%) LRP, n (%) RARP, n (%)
No. of men receiving RP 6 873 5 479 4 947
Year of RP
2008 1 228 (17.9) 496 (9.1) 280 (5.7)
2009 1 667 (24.3) 1 118 (20.4) 716 (14.5)
2010 1 487 (21.6) 1 255 (22.9) 952 (19.2)
2011 1 326 (19.3) 1 320 (24.1) 1 356 (27.4)
2012 1 165 (17.0) 1 290 (23.5) 1 643 (33.2)
Age
<60 years 1 929 (28.1) 1 702 (31.1) 1 760 (35.6)
60–69 years 4 119 (59.9) 3 258 (59.5) 2 740 (55.4)
>70 years 825 (12.0) 519 (9.5) 447 (9.0)
RCS Charlson comorbidity score
0 5 625 (81.8) 4 539 (82.8) 4 218 (85.3)
≥1 1 248 (18.2) 940 (17.2) 729 (14.8)
Socio-economic deprivation
1 (least deprived) 1 474 (21.5) 1 383 (25.2) 1 575 (31.8)
2 1 732 (25.2) 1 287 (23.5) 1 220 (24.7)
3 1 502 (21.9) 1 168 (21.3) 920 (18.6)
4 1 187 (17.3) 970 (17.7) 731 (14.8)
5 (most deprived) 978 (14.2) 671 (12.3) 501 (10.1)
Pelvic lymph node dissection
No 4 254 (61.9) 4 514 (82.4) 4 083 (82.5)
Yes 2 619 (38.1) 965 (17.6) 864 (17.5)
RP centre volume
<50 RPs/year 2 808 (40.8) 2 171 (39.6) 904 (18.2)
50–100 RPs/year 3 201 (46.5) 3 053 (55.7) 2 025 (40.9)
>100 RPs/year 864 (12.6) 2 025 (4.7) 2 018 (40.8)
RARP, robot-assisted radical prostatectomy; LRP, laparoscopic radical prostatectomy;
ORP, retropubic open radical prostatectomy; RCS, Royal College of Surgeons.
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lower in men who underwent LRP (adjusted OR 0.86; 95% CI
0.77–0.96).
Table 2 also shows that, over the study period, there was a
signiﬁcant trend towards fewer men experiencing urinary
complications after RP, even with adjustment for the
increasing use of RARP (P < 0.01 for any urinary and
stricture-related complications).
Impact of Type of Radical Prostatectomy on
Stricture-Related Complications
A total of 3.3% of men who received RARP required a
surgical intervention to treat a stricture-related urinary
complication within 2 years of RP compared with 5.7% of
men after LRP and 6.9% after ORP (Table 2 and Fig. 3).
Multi-level analysis showed that men who underwent RARP
had a signiﬁcantly lower risk of experiencing a stricture-
related complication than men who underwent ORP (adjusted
OR 0.44, 95% CI 0.35–0.56; Table 2) and the rate was also
lower in men who underwent LRP (adjusted OR 0.62, 95% CI
0.52–0.73).
A sensitivity analysis was performed including the 825 men
who received adjuvant or salvage radiotherapy (n = 18 124).
Multi-level analysis showed similar results to those of the
primary analysis; RARP was associated with fewer urinary
and stricture-related complications compared with ORP.
Discussion
Men who underwent RARP experienced signiﬁcantly fewer
severe urinary complications within 2 years of surgery than
men who underwent either ORP or LRP. Stricture-related
complications occurred most frequently in men who received
ORP and least frequently in men who underwent RARP.
The present study has a number of strengths. First, we used a
rigorously validated outcome measure designed to capture
urinary complications severe enough to require an
intervention after RP, comparable to grade 3 toxicity [17].
Second, this study reports real-world national data from the
English NHS, without limits on age and socio-economic or
insurance status, thereby overcoming a weakness of all
existing population-based studies. Third, we captured
complications requiring readmissions to all NHS hospitals
and not only to tertiary centres where the surgery was
performed, which is a common cause of under-reporting of
complications in many existing studies.
The study period encompassed the transition from open to
minimally invasive RP in England and therefore allowed a
comparison of groups that were of similar size, and all
included patients had at least 2 years of follow-up so that we
could accurately determine medium-term urinary
complications. A limitation of this approach is that a
‘learning curve’ for minimally invasive surgery may have had
an impact on the results. Although we were not able to adjust
for surgeon experience or volume, which has been shown to
be inversely related to complications after RP [19–21], we
were able to account for RP centre volume and showed that
it was not signiﬁcantly associated with the rates of any
urinary and stricture-related complication.
A limitation of using procedure codes as a surrogate for
urinary complications is that men who were symptomatic but
did not undergo an intervention were not captured.
Procedural codes were used as opposed to diagnostic codes as
they have been shown to have a higher coding accuracy [22].
In the UK, the vast majority of procedures we used as a
surrogate for complications are performed in the day-case/
inpatient setting and captured in the HES extract we used.
A small proportion of procedures will be performed in the
outpatient setting but these data were not available. As such,
the overall burden of urinary complications is likely to be an
underestimate, although we would not expect this to change
the comparative beneﬁt found to be associated with RARP in
the present study. The quality of HES data is dependent on
the accuracy of inputted data by administrative coders, and
particularly procedural codes within the context of this study;
however, a systematic review compared procedural codes to
medical records and found a high coding accuracy (84%) for
all studies [22].
A further limitation of the present study, as with many other
published population-based studies, is the lack of adjustment
for tumour stage and other disease characteristics, such as
PSA level, which were not available. In the English NHS this
may have less of an impact than in other healthcare systems
because the decision to proceed to surgery is coordinated
through a multidisciplinary team using national guidelines,
which limits the variation in stage for men receiving RP.
Furthermore, the choice of type of surgery depends on what
type is available at a particular hospital rather than on
individual patient characteristics. In addition to tumour stage
we were also unable to adjust for other factors including
margin status and nerve-sparing status. These data are
currently being collected by the National Prostate Cancer
Audit [23], and data linkage has been performed which will
allow adjustments for these factors in the future. We were
also not able to capture speciﬁc complications such as a
postoperative anastomotic leak as the operative and
radiological interventions are not accurately captured within
the OPCS-4 manual.
We found that stricture-related complications occurred most
frequently in men who underwent ORP, followed by men
who underwent LRP, and occurred least often in men who
underwent RARP. Our ﬁndings are consistent with a
population-based study in the USA of nearly 9000 Medicare-
insured men aged ≥65 years, which recruited from 2003 to
4
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2007 and demonstrated increased urethral stricture formation
within 1 year in the group undergoing ORP compared with
those undergoing minimally invasive RP [24]. The present
ﬁndings are in contrast, however, to the results of a meta-
analysis from 2009 that compared three types of RP across
many outcomes measures, including stricture formation [2].
Three of the studies included in that meta-analysis examined
RARP and no differences were found in stricture rates
between LRP and RARP or between ORP and RARP [25–27].
Given these differences in results, it is important to note that
the present study reports on a more recent cohort of men
without exclusions based on age or insurance status. Also, the
complications were identiﬁed with a validated tool that only
considers complications that required a hospital admission or
a procedural intervention, eliminating bias associated with
studies based on clinician-reported complications.
The present study also shows a trend that has been reported
in other US studies [28,29], which is that patients undergoing
minimally invasive surgery were less likely to undergo pelvic
lymph node dissection than those receiving ORP. This may
be related to the learning curve of minimally invasive surgery,
the extra time associated with carrying out the procedure
and/or the potential desire to limit complications.
We also found that men from more deprived socio-economic
backgrounds were more likely to experience urinary
complications. This association has not been previously
reported in prostate cancer surgery, but other studies have
reported higher complications rates in patients from more
deprived backgrounds after breast cancer [30] and coronary
artery bypass surgery [31].
Radical prostatectomy is a modular operation consisting of a
number of different steps, many of which are similar
irrespective of the surgical technique. The vesico-urethral
anastomosis (VUA), however, is one step of the operation
that is performed differently depending on the type of RP.
During RARP, the VUA is performed using a continuous
suture to achieve a watertight join. This is facilitated by the
robotic platform as the instruments enable the surgeon to
pass the suture needle through a number of acute
angles within the conﬁned space of the bony pelvis [32]. In
contrast, laparoscopic or open surgery usually uses between
four and six interrupted sutures to approximate the bladder
and urethra [33]. As a result, there is likely to be a higher
incidence of urinary leakage from the VUA, which can result
in increased scarring/ﬁbrosis around the anastomosis, with
subsequent stricture formation [34,35]. Furthermore, when
performing RARP, a posterior reconstruction (Rocco) suture
is often placed, which is another step often not performed
during either LRP or ORP. This posterior reconstruction
suture approximates the urethral rhabdosphincter, which may
reduce tension on the VUA and subsequently decrease
stricture formation [36].
Robot-assisted prostate cancer surgery has been rapidly
adopted in many countries and has become the most
Numbers at risk
Time, years 0 0.5 1 1.5 2
ORP 6873 5983 5752 5620 5509
LRP 5479 4935 4785 4680 4578
RARP 4947 4646 4559 4484 4393
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Fig. 2 Kaplan–Meier failure curves for any urinary complication stratiﬁed
by type of radical prostatectomy. RARP, robot-assisted radical
prostatectomy; LRP, laparoscopic radical prostatectomy; ORP, retropubic
open radical prostatectomy.
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Fig. 3 Kaplan–Meier failure curves for stricture-related urinary complication
stratiﬁed by type of radical prostatectomy. RARP, robot-assisted radical
prostatectomy; LRP, laparoscopic radical prostatectomy; ORP, retropubic
open radical prostatectomy.
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common type of RP within the English NHS [37]. Attempts
to estimate whether the increased healthcare costs associated
with RARP are cost-effective are still hampered by
uncertainty around improvements in outcomes such as cancer
control and medium-term morbidity [38]. Our results
emphasize that there are additional advantages to RARP in
the long term, which not only improve patient outcomes but
reduce subsequent treatment costs in healthcare systems.
These data will be crucial in supplementing future longer-
term data to be released from an ongoing RCT [7].
In conclusion, in this national population-based study in men
with non-metastatic prostate cancer, we have shown that men
who underwent RARP were less likely to require an
intervention and hospital admission for a urinary
complication than those who underwent LRP or ORP. This
has long-term functional beneﬁts for patients undergoing RP,
and the morbidity outcomes from the present study provide
further means by which to strengthen economic models
evaluating the cost-effectiveness of RARP.
Acknowledgements
J. van der Meulen is partly supported by the NHS National
Institute for Health Research Collaboration for Leadership in
Applied Health Research and Care North Thames at Bart’s
Health NHS Trust. The views expressed in this publication
are those of the authors and not necessarily those of the
NHS, the NHS National Institute for Health Research, or the
Department of Health. A. Aggarwal is funded by a Doctoral
Research Fellowship from the NHS National Institute for
Health Research. M. Parry is partly supported by the NHS
National Institute for Health Research through an Academic
Clinical Fellowship. H. Payne was supported by the UCLH/
UCL Comprehensive Biomedical Research Centre. P.
Dasgupta acknowledges support from the Vatikuti
Foundation grant to the Institute of Robotic Surgery, King’s
College London. HES data were made available by the NHS
Health and Social Care Information Centre (© 2012, Re-used
with the permission of NHS Digital. All rights reserved.) The
cancer registry data used for this study are based on
information collected and quality assured by Public Health
England’s National Cancer Registration and Analysis Service.
Access to the data was facilitated by the Public Health
England’s Ofﬁce for Data Release. A. Sujenthiran, J. Nossiter,
S. C. Charman, M. Parry, J. van der Meulen, P. Cathcart, N.
W. Clarke, H. Payne and A. Aggarwal are members of the
Project Team of the National Prostate Cancer Audit (www.
npca.org.uk) funded by the Healthcare Quality Improvement
Partnership (http://www.hqip.org.uk/).
Conﬂict of Interest
H. Payne has attended and received honoraria for advisory
boards, travel expenses to medical meetings and served as a
consultant for AstraZeneca, Astellas, Janssen, Sanoﬁ Aventis,
Takeda, Ipsen, Ferring, Sandoz and Novartis. J. van der
Meulen reports a contract with the Healthcare Quality
Improvement Partnership for the provision of a national
evaluation of prostate cancer services in England and Wales
during the conduct of the study. All other authors have no
conﬂicts of interest to declare.
References
1 Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreaden U, Hebert
AE, Wiklund P. Positive surgical margin and perioperative complication
rates of primary surgical treatments for prostate cancer: a systematic
review and meta-analysis comparing retropubic, laparoscopic, and robotic
prostatectomy. Eur Urol 2012; 62: 1–15
2 Ficarra V, Novara G, Artibani W et al. Retropubic, laparoscopic, and
robot-assisted radical prostatectomy: a systematic review and cumulative
analysis of comparative studies. Eur Urol 2009; 55: 1037–63
3 Novara G, Ficarra V, Rosen RC et al. Systematic review and meta-
analysis of perioperative outcomes and complications after robot-assisted
radical prostatectomy. Eur Urol 2012; 62: 431–52
4 Gandaglia G, Sammon JD, Chang SL et al. Comparative effectiveness of
robot-assisted and open radical prostatectomy in the postdissemination
era. J Clin Oncol 2014; 32: 1419–26
5 Trinh Q-D, Sammon J, Sun M et al. Perioperative outcomes of robot-
assisted radical prostatectomy compared with open radical prostatectomy:
results from the nationwide inpatient sample. Eur Urol 2012; 61: 679–85
6 Leow JJ, Chang SL, Meyer CP et al. Robot-assisted versus open radical
prostatectomy: a contemporary analysis of an all-payer discharge
database. Eur Urol 2016; 70: 837–45
7 Yaxley JW, Coughlin GD, Chambers SK et al. Robot-assisted
laparoscopic prostatectomy versus open radical retropubic prostatectomy:
early outcomes from a randomised controlled phase 3 study. Lancet 2016;
388: 1057–66
8 Sujenthiran A, Charman SC, Parry M et al. Quantifying severe urinary
complications after radical prostatectomy: the development and validation
of a surgical performance indicator using hospital administrative data.
BJU Int 2017;120:219–25
9 ICD-10 International Classiﬁcation of Diseases (10th revised edition).
Available at: https://digital.nhs.uk/article/1117/Clinical-Classifications.
Accessed December 2016
10 English Cancer Registry Data. Available at: http://www.ncin.org.uk/collec
ting_and_using_data/national_cancer_data_repository. Accessed December
2016
11 OPCS-4 classiﬁcation of interventions and procedures. Available at:
https://digital.nhs.uk/article/1117/Clinical-Classifications. Accessed
December 2016
12 Hospital Episode Statistics. Available at: http://www.hesonline.nhs.uk.
Accessed December 2016
13 Noble MD, Wilkinson K, Whitworth A, Dibben C, Barnes H. The
English Indices of Deprivation, London: HMSO, 2007
14 Armitage JN, van der Meulen JH, Group Royal College of Surgeons
Co-morbidity Consensus Group. Identifying co-morbidity in surgical
patients using administrative data with the Royal College of Surgeons
Charlson Score. Br J Surg 2010;97:772–81
15 Leow JJ, Leong EK, Serrell EC et al. Systematic review of the volume &
outcome relationship for radical prostatectomy: a 2017 update. Eur Urol
Focus 2017; pii: S2405-4569(17)30076-7. https://doi.org/10.1016/j.euf.2017.
03.008. [Epub ahead of print]
16 NHS England; Clinical commissioning policy: Robotic-assisted surgical
procedures for prostate cancer 2015. Available at: https://www.england.
© 2017 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International 7
Urinary complications after RARP vs LRP vs ORP
nhs.uk/commissioning/wp-content/uploads/sites/12/2015/10/b14pa-rbtic-
asstd-srgry-prostate-cancer-oct15.pdf. Accessed December 2016
17 Common Terminology Criteria for Adverse Events (CTCAE). National
Institute of Health. National Cancer Institute. Available at: https://www.
eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
Accessed December 2016
18 Mitropoulos D, Artibani W, Graefen M, Remzi M, Roupret M, Truss M.
Reporting and grading of complications after urologic surgical procedures:
an ad hoc EAU guidelines panel assessment and recommendations. Eur
Urol 2012; 61: 341–9
19 Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of surgeon
volume in radical prostatectomy outcomes. J Clin Oncol 2003; 21: 401–5
20 Almatar A, Wallis CJD, Herschorn S et al. Effect of radical
prostatectomy surgeon volume on complication rates from a large
population-based cohort. Can Urol Assoc J 2016; 10: 45–9
21 Barocas DA, Mitchell R, Chang SS, Cookson MS. Impact of surgeon and
hospital volume on outcomes of radical prostatectomy. Urol Oncol 2010;
28: 243–50
22 Burns EM, Rigby E, Mamidanna R et al. Systematic review of discharge
coding accuracy. J Public Health (Oxf) 2012; 34: 138–48
23 National Prostate Cancer Audit (NPCA) Team (Sujenthiran A, Nossiter
J et al.). NPCA 3rd Annual Report 2016
24 Hu JC, Gu X, Lipsitz SR et al. Comparative effectiveness of minimally
invasive vs open radical prostatectomy. JAMA 2009; 302: 1557–64
25 Krambeck AE, DiMarco DS, Rangel LJ et al. Radical prostatectomy for
prostatic adenocarcinoma: a matched comparison of open retropubic and
robot-assisted techniques. BJU Int 2009; 103: 448–53
26 Joseph JV, Vicente I, Madeb R, Erturk E, Patel HR. Robot-assisted vs
pure laparoscopic radical prostatectomy: are there any differences? BJU
Int 2005; 96: 39–42
27 Hu JC, Nelson RA, Wilson TG et al. Perioperative complications of
laparoscopic and robotic assisted laparoscopic radical prostatectomy. J
Urol 2006; 175: 541–6
28 Prasad SM, Keating NL, Wang Q et al. Variations in surgeon volume
and use of pelvic lymph node dissection with open and minimally
invasive radical prostatectomy. Urology 2008; 72: 647–52
29 Alemozaffar M, Sanda M, Yecies D, Mucci LA, Stampfer MJ, Kenﬁeld
SA. Benchmarks for operative outcomes of robotic and open radical
prostatectomy: results from the Health Professionals Follow-up Study. Eur
Urol 2015; 67: 432–8
30 Jeevan R, Browne JP, Pereira J et al. Socioeconomic deprivation and
inpatient complication rates following mastectomy and breast
reconstruction surgery. Br J Surg 2015; 102: 1064–70
31 Gibson PH, Croal BL, Cuthbertson BH et al. Socio-economic status and
early outcome from coronary artery bypass grafting. Heart 2009; 95: 793–8
32 Albisinni S, Aoun F, Peltier A, van Velthoven R. The single-knot
running vesicourethral anastomosis after minimally invasive
prostatectomy: review of the technique and its modiﬁcations, tips, and
pitfalls. Prostate Cancer 2016; 2016: 1481727
33 Walsh PC. Anatomic radical prostatectomy: evolution of the surgical
technique. J Urol 1998; 160(6 Pt 2): 2418–24
34 Kostakopoulos A, Argiropoulos V, Protogerou V, Tekerlekis P, Melekos
M. Vesicourethral anastomotic strictures after radical retropubic
prostatectomy: the experience of a single institution. Urol Int 2004; 72:
17–20
35 Fridriksson JO, Folkvaljon Y, Lundstrom KJ, Robinson D, Carlsson S,
Stattin P. Long-term adverse effects after retropubic and robot-assisted
radical prostatectomy. Nationwide, population-based study. J Surg Oncol
2017; 116: 500–6
36 Rocco F, Rocco B. Anatomical reconstruction of the rhabdosphincter
after radical prostatectomy. BJU Int 2009; 104: 274–81
37 National Prostate Cancer Audit (NPCA) Team (Sujenthiran A, Nossiter
J et al.). NPCA 2nd Annual Report 2015 – Further analysis of existing
clinical data and preliminary results from the NPCA Prospective Audit
38 Schroeck FR, Jacobs BL, Bhayani SB, Nguyen PL, Penson D, Hu J. Cost
of new technologies in prostate cancer treatment: systematic review of
costs and cost effectiveness of robotic-assisted laparoscopic prostatectomy,
intensity-modulated radiotherapy, and proton beam therapy. Eur Urol
2017;72:712–35
Correspondence: Arunan Sujenthiran, Clinical Effectiveness
Unit, Royal College of Surgeons, 35-43 Lincoln’s Inn Fields,
London WC2A 3PE, UK.
e-mail: asujenthiran@doctors.org.uk
Abbreviations: HES, Hospital Episodes Statistics; ICD-10,
International Classiﬁcation of Diseases, 10th revision; LRP,
laparoscopic radical prostatectomy; OPCS-4, Ofﬁce of
Population Census and Surveys classiﬁcation, 4th revision;
OR, odds ratio; ORP, retropubic open radical prostatectomy;
RARP, robot-assisted radical prostatectomy; RP, radical
prostatectomy; VUA, vesico-urethral anastomosis.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1 OPCS-4 and ICD-10 codes used to identify men
receiving adjuvant/salvage radiotherapy and pelvic lymph
node dissection.
Table S2 List of interventions used to treat all urinary
complications (stricture-related interventions shaded in grey).
8
© 2017 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International
Sujenthiran et al.
